Role of nitric oxide in tumor progression: Lessons from human tumours

Cancer and Metastasis Reviews

Volumn 17, Issue 1, 1998, Pages 107-118

  Thomsen, Lindy L ^a   Miles, David W ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Cancer; Human; Inhibition; Invasion; Nitric oxide

Indexed keywords

NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR;

ANGIOGENESIS; BREAST CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INVASION; CENTRAL NERVOUS SYSTEM TUMOR; ENZYME ACTIVITY; ENZYME INHIBITION; GROWTH REGULATION; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; METASTASIS POTENTIAL; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER;

DISEASE PROGRESSION; HUMANS; NEOPLASMS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II;

EID: 0031900542     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005912906436     Document Type: Review

References (60)

1. Moncada S, Palmer RMJ, Higgs EA: Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109-142, 1991
2. De Belder AJ, Radomski MW: Nitric oxide in the clinical arena. J Hypertension 12: 617-624, 1994
3. Knowles RG, Moncada S: Nitric oxide synthase in mammals. Biochem J 298: 249-258, 1994
4. Folkman J: What is the evidence that tumours are angiogenesis-dependent? J Natl Cancer Inst 82: 4-6, 1990
5. Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R, Della Porta G, Menard S, Pierotti M, Testori A: Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 49: 44-49, 1991
6. 0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol 7: 1239-1257, 1989
7. Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR: Expression of tumour necrosis factor (TNFα) and its receptor in benign and malignant breast tissue. Int J Cancer 56: 777-782, 1994
8. Radomski MW, Jenkins DC, Holmes L, Moncada S: Human colorectal adenocarcinoma cells: Differential nitric oxyde synthesis determines their ability to aggregate platelets. Cancer Res 51: 6073-6078, 1991
9. 2+/calmodulin-dependent nitric oxide synthase activity in the human cervix carcinoma cell line ME-180. Biochem J 289: 357-361, 1993
10. Sherman PA, Laubach VE, Reep BR, Wood ER: Purification and cDNA sequence of an inducible nitric oxide synthase from a human tumor cell line. Biochemistry 32: 11600-11605, 1993
11. Fujisawa H, Ogura T, Hokari A, Weisz A, Yamashita J, Esumi H: Inducible nitric oxide synthase in a human glioblastoma cell line. J Neurochemistry 64: 85-91, 1995
12. Monti E, Gariboldi M: Antiproliferative effects of interleukin-1α and nitric oxide release in a human ovarian carcinoma cell line. Proc Am Assoc Cancer Res 35: 484, 1994
13. Thomsen LL, Miles DW, Jenkins DC, Affleck K, Holmes L, Moncada S: Nitric oxide synthase in human breast cancer is expressed in stromal cells and not in tumour cells or in human breast tumour cell lines. Br J Cancer 71: 18, 1995
14. Jenkins DC, Charles IG, Baylis SA, Lelchuk R, Radomski MW, Moncada S: Human colon cancer cell lines show a diverse pattern of nitric oxide synthase gene expression and nitric oxide generation. Br J Cancer 70: 847-849, 1994
15. Thomsen LL, Lawton FG, Knowles RG, Beesley JE, Riveros-Moreno V, Moncada S: Nitric oxide synthase activity in human gynecological cancer. Cancer Res 54: 1352-1354, 1994
16. Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG, Moncada S: Nitric oxide synthase activity in human breast cancer. Br J Cancer 72: 41-44, 1995
17. Cobbs CS, Brenman JE, Aldape KD, Bredt DS, Israel MA: Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res 55: 727-730, 1995
18. Thomsen LL, Farais-Eisner R, Chaudhuri G: Nitric oxide: Role in human cervical cancer. In: Moncada S, Stamler J, Gross S, Higgs EA (eds) The Biology of Nitric Oxide Part 5. Proceedings of the 4th International Meeting on the Biology of Nitric Oxide. Portland Press, London, 1996, p289
19. Miles DW, Happerfield LC, Thomsen LL, Filipe I: Nitric oxide synthase and localisation in gastric carcinoma. Proc Am Assoc Cancer Res 37: 154, 1996
20. Hibbs JB, Taintor RR, Vavrin Z, Rachlin EM: Nitric oxide: A cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 157: 87-94, 1988
21. Drapier J-C, Wietzerbin J, Hibbs JB: Interferon-γ and tumour necrosis factor induce the L-arginine-dependent cytotoxic effector mechanism in murine macrophages. Eur J Immunol 18: 1587-1592, 1988
22. Keller R, Geiges M, Keist R: L-arginine-dependent reactive nitrogen intermediates as mediators of tumor cell killing by activated macrophages. Cancer Res 50: 1421-1425, 1990
23. Xie K, Huang S, Dong Z, Juang S-H, Gutman M, Xie Q-W, Nathan C, Fidler IJ: Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med 181: 1333-1343, 1995
24. Thomsen LL, Baguley BC, Wilson WR: Nitric order: Its production in host-cell-infiltrated EMT6 spheroids and its role in tumour cell killing by flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 31: 151-155, 1992
25. Liew FY, Millott S, Parkinson C, Palmer RMJ, Moncada S: Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol 144: 4794-4797, 1990
26. Garth LL, Nicholson GL, Fidler IJ: Direct in vitro lysis of metastatic tumor cells by cytokine-activated murine vascular endothelial cells. Cancer Res 51: 245-254, 1991
27. Li L, Kilbourn RG, Adams J, Fidler IJ: Role of nitric oxide in lysis of tumor cells by cytokine-activated endothelial cells. Cancer Res 51: 2531-2535, 1991
28. Denis M: Tumor necrosis factor and granulocyte macrophage-colony stimulating factor stimulate human macrophages to restrict growth of virulent Mycobacterium avium and to kill avirulent M. avium. J Leukocyte Biol 49: 380-387, 1991
29. Cameron ML, Granger DL, Weinberg JB, Kozumbo WJ, Koren HS: Human alveolar and peritoneal macrophages mediate fungistasis independently of L-arginine oxidation to nitrite or nitrate. Am Rev Respir Dis 142: 1313-1319, 1990
30. Murray HW, Teitelbaum RF: L-arginine-dependent reactive nitrogen intermediates and the antimicrobial effect of activated mononuclear phagocytes. J Infect Dis 165: 513-518, 1992
31. Schneemann M, Schoedon G, Hofer S, Blau N, Guerrero L, Schaffner A: Nitric oxide synthase is not a constituent of the antimicrobial armature of human mononuclear phagocytes. J Infect Dis 167: 1358-1364, 1993
32. Dugas B, Mossalayi D, Damais C, Kolb J-P: Nitric oxide production by human monocytes: Evidence for a role of CD23. Immunol Today 16: 574-580, 1995
33. Mossalayi MD, Paul-Eugene N, Ouaaz F, Arock M, Koln JP, Kilchherr E, Debre P, Dugas B: Involvement of FcεRII/ CD23 and L-arginine-dependent pathway in IgE-mediated stimulation of human monocyte functions. Internat Immunol 6: 931-934, 1994
34. Miles DW, Happerfield LC, Rubens RD: Localisation of nitric oxide synthase (NOS) isoforms and co-expression of the low affinity IgE receptor (CD23) in primary breast cancer. Proc Am Assoc Cancer Res 37: 238, 1996
35. Lorenzen J, Lewis CE, McCracken D, Horak E, Greenall M, McGee JO: Human tumor-associated NK cells secrete increased amounts of interferon-gamma and interleukin-4. Br J Cancer 64: 457-462, 1991
36. Scholl SM, Pallud C, Beuvon F, Hacene K, Stanley ER, Rohrschneider L, Tang R, Pouillard P, Lidereau R: Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst 86: 120-126, 1994
37. Jenkins DC, Charles IG, Thomsen LL, Moss DW, Holmes LS, Baylis SA, Rhodes P, Westmore K, Emson PC, Moncada S: Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA 92: 4392-4396, 1995
38. Leibovich SJ, Polverini PJ, Fong TW, Harlow LA, Koch AE: Production of angiogenic activity by human monocytes requires an L-arginine/nitric oxide-synthase-dependent affector mechanism. Proc Natl Acad Sci USA 91: 4190-4194, 1994
39. Konturek S, Brzozowski T, Majka J, Pytko-Polonczyk J, Stachura J: Inhibition of nitric oxide synthase delays healing of chronic gastric ulcers. Eur J Pharmacol 239: 215-217, 1993
40. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA: Relation of neovascularisation to metastasis of non-small cell lung cancer. Lancet 340: 145-146, 1992
41. Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast cancer. N Engl J Med 324: 1-8, 1991
42. Fidler IJ, Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79: 185-188, 1994
43. Kohn EC, Liotta LA: Molecular insights into cancer invasion: Strategies for prevention and intervention. Cancer Res 55: 1856-1862, 1995
44. Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR: Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 67: 1126-1131, 1993
45. Murrell GAC, Jang D, Williams RJ: Nitric oxide activates metalloprotease enzymes in articular cartilage. Biochem Biophys Res Commun 206: 15-21, 1995
46. Tamura T, Nakanishi T, Kimura Y, Sasaki K, Norimatsu H, Takahashi K, Takigawa M: Nitric oxide mediates interleukin-1 induced matrix degradation and basic fibroblast growth factor release in cultured rabbit articular chondrocytes: A possible mechanism of pathological neovascularization in arthritis. Endocrinology 137: 3729-3737, 1996
47. Hibbs JB, Westenfelder C, Taintor R, Vavrin Z, Kabbitz C, Bararowski RL: Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J Clin Invest 89: 867-877, 1992
48. Ochoa JB, Curti B, Peitzman AB, Simmons RL, Billiar TR, Hoffman R, Rault R, Longo DL, Urba WJ, Ochoa AC: Increased circulating nitrogen oxides after human tumor immunotherapy: Correlation with toxic hemodynamic changes. J Natl Cancer Inst 84: 864-867, 1992
49. Miles DW, Thomsen LL, Balkwill F, Thavasu P, Moncada S: Association between biosynthesis of nitric oxide and changes in immunological and vascular parameters in patients treated with interleukin-2. Eur J Cin Invest 24: 287-290, 1994
50. Citterio G, Pellegatta F, Dilucca G, Fragasso G, Scagleitti U, Pini D, Fortis C, Tresoldi M, Rugarli C: Plasma nitrate plus nitrite changes during continuous intravenous infusion of interleukin-2. Br J Cancer 74: 1297-1301, 1996
51. Ogilvie AC, Hack CE, Wagstaff J, Van Mierlo GJ, Erenberg AJ, Thomsen LL, Hoekman K, Rankin EM: IL-1 beta does not cause neutrophil degranulation, but does lead to IL-6, IL-8 and nitrite/nitrate release when used in patients with cancer. J Immunol 156: 389-394, 1996
52. Thomsen LL, Baguley BC, Rustin GJS, O'Reilly SM: Flavone acetic acid (FAA) with recombinant interleukin-2 (TIL-2) in advanced malignant melanoma II: Induction of nitric oxide production. Br J Cancer 66: 723-727, 1992
53. Moilanen E, Thomsen LL, Miles DW, Happerfield L, Knowles RG, Moncada S: Persistent induction of nitric oxide synthase in tumors from mice following treatment with the antitumor agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer (in press)
54. Andrade SP, Hart IR, Piper PJ: Inhibitors of nitric oxide synthase selectively reduce flow in tumour-associated neovasculature. Br J Pharmacol 107: 1092-1095, 1992
55. Wood PJ, Stratford IJ, Adams GE, Szabo C, Thiemermann C, Vane JR: Modification of energy metabolism and radiation response of a murine tumour by changes in nitric oxide availability. Biochem Biophys Res Commun 192: 505-510, 1993
56. Peterson HI: Modification of tumour blood flow - a review. Int J Radiat Biol 60: 201-210, 1991
57. Rees DD, Palmer RMJ, Schulz R, Hodson HF, Moncada S: Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 101: 746-752, 1990
58. Garvey EP, Oplinger JA, Furfine ES, Kiff RJ, Laszlo F, Whittle BJR, Knowles RG: 1400W is a slow tight binding, and highly selective inhibitor of inducible nitric oxide synthase in vitro and in vivo. J Biol Chem 272: 4959-4963, 1997
59. Omerovic I, Thomsen LL: Differential expression of nitric oxide synthase in five murine tumors. Proc Am Assoc Cancer Res 37: 493, 1996
60. Thomsen LL, Scott JMJ, Topley P, Knowles RG, Keerie A-J, Frend AJ: Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo. Studies with 1400W, a novel inhibitor. Cancer Res 57: 3300-3304, 1997